ibs
Understanding the complex interactions between exercise, diet and gut health can help to develop approaches to influence the gut microbiota, boost immunity and prevent or manage gastrointestinal diseases.
Launching a new frontier in IBS management: the 'TrIuMPH' trial sets the stage with EBX-102-02, a pioneer in microbiome-based therapy.
Giovanni Barbara, congress chair, explain why it is important to be part of IBS Days 2024.
According to the authors, results suggest that patients with a specific microbial signature have a more favorable response to therapy.
The gut microbiota can be useful to distinguish between IBD and IBS. That's according to a study published in Science Translational Medicine.
